ClinicalTrials.gg
RecruitingNCT06154707Updated Aug 16, 2024

Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

A Phase 3 interventional study of Denosumab Injection and Normal saline injection (1.0ml/ branch) in Sarcopenia, Osteoporosis and Denosumab, sponsored by Wuhan Union Hospital, China. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Wuhan Union Hospital, China · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.

Planned enrollment
35th of 52
86 · median 110
Started
2024
with 12 others
Phase 3
4 of 83
4 open now
Primary completion
2024-12
later than 7 of 51 live
Registered
31st of 83
by date

Among the 83 studies in Sarcopenia with a site in China, this one is the 35th largest by planned enrollment of the 52 interventional ones that give a count, is one of 13 that started in 2024, is one of 4 in phase 3, reaches primary completion later than 7 of the 51 other live ones, and was the 31st registered.

Sarcopenia

1,333 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Sarcopenia with a site in China, or all of them as a file.
02

Study summary

Through the method of a clinical randomized controlled trial, patients meeting the study criteria are randomly assigned to either the Denosumab treatment group or a placebo group. After a treatment period of 12 months, the differences in osteoporosis and sarcopenia-related baseline assessment changes between the two groups are compared. This is to explore the effect of Denosumab in treating osteoporosis and its impact on sarcopenia. The goal is to evaluate the efficacy of Denosumab in treating osteoporosis in the domestic population and its related impact on sarcopenia, with the aim of providing an effective treatment option for the domestic population suffering from 'osteoporosis-sarcopenia syndrome.

03

Conditions studied

  • Sarcopenia
  • Osteoporosis
  • Denosumab
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of /senile osteoporosis after examination and assessment.
  • Clinical diagnosis of postmenopausal/senile osteoporosis combined with sarcopenia after examination and assessment.
  • Have not previously taken any other anti-osteoporosis drugs.

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of pathological fractures.
  • Have participated in another clinical trial within the past 3 months or have taken other anti-osteoporosis drugs within the past 6 months.
  • Severe chronic metabolic diseases or serious organ failure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Denosumab Group

    Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.

    Drug: Denosumab Injection

  • Placebo comparator
    Placebo Group

    Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements. The study lasted for 12 months.

    Other: Normal saline injection (1.0ml/ branch)

Interventions

  • DrugDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.

  • OtherNormal saline injection (1.0ml/ branch)

    Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.

06

What researchers measure

Primary outcomes

  1. Osteoporosis-related Primary Outcome

    Bone mineral density (BMD) changed from baseline after 6 and 12 months of treatment in both groups. (DXA method, T value has no specific unit of measure) Bone transformation markers (BTM) changed from baseline after 6 and 12 months of treatment in both groups. (Total P1NP(ng/ml), total 25 hydroxyvitamin D(nmol/L), osteocalcin N-terminal fragment(ng/ml), βCrossLap(pg/ml)) After 6 and 12 months of treatment, osteoporosis related blood biochemistry(TBIL, DBIL, Cr, UA, HCY in umol/L, BUN, TC, TG, HDL, LDL, Ca, IP in mmol/L, ALB, PAB in g/L, CK, ALT, AST, GGT in U/L), blood routine(WBC, PLT, NEU, LYMPH, MONO, EOS in G/L, RBC in T/L, HGB in g/L), inflammatory indicators(IL-1β, TNF-α, IL-6 in pg/mL), and related hormones(PTH, CT in ng/L) changed from baseline. Changes in the above indicators from the baseline are possible or hypothetical, and all are subject to experimental results.

    Time frame: 1 year

  2. Sarcopenia-related Primary Outcome

    After 6 and 12 months of treatment, the SARC-F scale was evaluated compared with baseline.(No unit of measure) After 6 and 12 months of treatment, muscle strength (dominant hand grip strength, Kg) changed from baseline in both groups. After 6 and 12 months of treatment, skeletal muscle mass (ASM in Kg), skeletal muscle mass index (ASM and height will be combined to report ASMI in Kg/m²), body fat percentage(%) and limb fat percentage(%)in both groups were changed from baseline. (BIA method) After 6 and 12 months of treatment, the walking speed of 6 M(m/s) and the sitting time of 5 times(s) were changed from baseline. Changes in the above indicators from the baseline are possible or hypothetical, and all are subject to experimental results.

    Time frame: 1 year

Secondary outcomes

  1. Quality of life and fall risk

    Changes in quality of life and fall risk from baseline were assessed using the abbreviated Health Survey Form (SF-36) and the Morse Fall Risk Assessment Scale at the end of 12 months of treatment in both groups.(The score has no specific unit of measure) Changes in the above scale from the baseline are possible or hypothetical, and all are subject to experimental results.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Dec 4, 2023
StartActual
Feb 1, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Mar 1, 2025
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06154707
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Feb 1, 2024
Primary completion
Dec 31, 2024 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Aug 16, 2024

Study contacts

Wen Peng
Contact
pengwen666@sina.com
13986074846
ShaoTian Li
Contact
1398998676@qq.com
18300850090

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion